Anti-AKR1D1 Antibody Picoband®, Cy3 Conjugate

Human delta (4)-3-oxosteroid 5-beta-reductase (steroid 5-beta-reductase) catalyzes 5-beta-reduction of bile acid intermediates and steroid hormones carrying a delta (4)-3-one structure. This gene is mapped to 7q33. The enzyme encoded by this gene is responsible for the catalysis of the 5-beta-reduction of bile acid intermediates and steroid hormones carrying a delta (4)-3-one structure. Deficiency of this enzyme may contribute to hepatic dysfunction. Three transcript variants encoding different isoforms have been found for this gene. Other variants may be present, but their full-length natures have not been determined yet.

Aldo-keto reductase family 1 member D1; 3-oxo-5-beta-steroid 4-dehydrogenase; Delta (4)-3-ketosteroid 5-beta-reductase; Delta (4)-3-oxosteroid 5-beta-reductase; AKR1D1; SRD5B1

A synthetic peptide corresponding to a sequence in the middle region of human SMAD5, which shares 95.5% amino acid (aa) sequence identity with both mouse and rat SMAD5.

Catalyzes the stereospecific NADPH-dependent reduction of the C4-C5 double bond of bile acid intermediates and steroid hormones carrying a delta4-3-one structure to yield an A/B cis-ring junction. This cis-configuration is crucial for bile acid biosynthesis and plays important roles in steroid metabolism. Capable of reducing a broad range of delta-4-3-ketosteroids from C18 (such as, 17beta-hydroxyestr-4-en-3-one) to C27 (such as, 7alpha-hydroxycholest-4-en-3-one).

1. Charbonneau, A., Luu-The, V. Assignment of steroid 5-beta-reductase (SRD5B1) and its pseudogene (SRD5BP1) to human chromosome bands 7q32-q33 and 1q23-q25, respectively, by in situ hybridization. Cytogenet. Cell Genet. 84: 105-106, 1999. 2. Charbonneau, A., The, V.-L. Genomic organization of a human 5-beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme. Biochim. Biophys. Acta 1517: 228-235, 2001. 3. Clayton, P. T., Mills, K. A., Johnson, A. W., Barabino, A., Marazzi, M. G. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Gut 38: 623-628, 1996.

Store at -20℃ for one year from date of receipt. After reconstitution, at 4℃ for one month. It can also be aliquotted and stored frozen at -20℃ for six months. Avoid repeated freeze-thaw cycles.

Western blot, 0.1-0.25μg/ml, Human, Mouse, Rat<br> Immunohistochemistry (Paraffin-embedded Section), 0.5-1μg/ml, Human<br> Immunocytochemistry/Immunofluorescence, 4μg/ml, Human<br> Flow Cytometry (Fixed), 1-3μg/1x10⁶ cells, Human<br>